Company e-therapeutics plc

Equities

ETX

GB00B2823H99

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:21 2024-04-24 am EDT			5-day change	1st Jan Change
9.175 ^GBX	+3.67%		-10.05%	+11.35%

Apr. 10	FTSE 100 Closes Up 0.3% as U.S. Uncertainty Boosts Appetite for U.K. Stocks	DJ
Apr. 10	E-Therapeutics says company faces lack of interest as UK listing	AN

e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

Number of employees: 34

GBP in Million	2022	Weight	2023	Weight	Delta
Drug Discovery 100.0 %	0	100.0 %	0	100.0 %	-0.42%

GBP in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	0	100.0 %	0	100.0 %	-0.42%

Managers	Title	Age	Since
Ahmad Mortazavi CEO	Chief Executive Officer	53	20-01-31
Timothy Bretherton DFI	Director of Finance/CFO	-	-
Alan Whitmore CTO	Chief Tech/Sci/R&D Officer	-	-
Laura Roca-Alonso COO	Chief Operating Officer	-	20-04-01
Michael Bretherton BRD	Director/Board Member	68	20-02-10
Alison Gallafent PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Trevor Jones CHM	Chairman	82	15-10-27
Michael Bretherton BRD	Director/Board Member	68	20-02-10
Ahmad Mortazavi CEO	Chief Executive Officer	53	20-01-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	584,335,487	237,003,079 ( 40.56 %)	0	40.56 %

Name	Equities	%	Valuation
Richard Griffiths 29.18 %	170,510,905	29.18 %	24 M p
M&G Investment Management Ltd. 17.43 %	101,875,000	17.43 %	14 M p
Robert Quested 8.899 %	52,000,000	8.899 %	7 M p
Ahmad Mortazavi 8.718 %	50,941,666	8.718 %	7 M p
Trillian Ltd. 5.095 %	29,769,326	5.095 %	4 M p
David Richardson 4.589 %	26,812,312	4.589 %	4 M p
Bank J. Safra Sarasin AG (Investment Management) 4.329 %	25,298,374	4.329 %	4 M p
Schroder Investment Management Ltd. 2.379 %	13,900,000	2.379 %	2 M p
Investec Wealth & Investment Ltd. 1.404 %	8,203,000	1.404 %	1 M p
Newcastle University Holding Ltd. 1.154 %	6,744,000	1.154 %	937 146 p

e-Therapeutics Plc

Paddington Central 4 Kingdom Street

W2 6BD, London

+44 20 4551 8888

http://www.etherapeutics.co.uk

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
E-THERAPEUTICS PLC	+11.35%	64.33M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research